Advanced Solid Tumors with KRAS Mutation
Advanced solid tumors with KRAS mutation refer to cancers that have progressed and contain a specific genetic change in the KRAS gene, which can affect treatment options and outcomes.
Advanced Solid Cancers: BAY 3498264 Study
We are investigating a new treatment for patients with advanced solid cancers that have the KRASG12C mutation. The study looks at how this treatment works alone and with another medication.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Rigshospitalet
Department of oncology
Copenhagen, Denmark
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Oncologia Medica
La Massimina-Casal Lumbroso, Italy
Humanitas Mirasole S.p.A.
Oncologia Medica ed Ematologia
Rozzano, Italy
Sponsor: Bayer AG
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.